Abstract
Subject Index
Abscesses, skin and soft tissue, 257–260
Acantholytic dermatosis of the crural folds (ADCF), 151–153
Acne inversa (hydradenitis suppurativa), 164–168
Acne vulgaris, 204–208
Acral syringomas, 169–171
Actinic dermatitis, 121–128
Adalimumab
alopecia areata following, 48–49
for psoriatic arthritis, 3
Adapalene, 186–187
Alefacept
AWARE study on, S107-S110
AWARE-2 study on, S148-S152
clinical experiences with, S113-S121
combination therapy with, S131-S137
cost, 303–307
for difficult-to-treat psoriasis, 10–12, 14–15
efficacy of, S122-S130
for nail psoriasis, 3
for psoriasis and vitiligo, 172–175
safety of, S139-S146
Allergic contact dermatitis (ACD)
chronic actinic dermatitis and, 121–128
in leg ulcer patients, S38-S41
Alopecia
androgenetic, 262–264
areata, 48–49
α1 Collagen, 129–133
Aluminum contact dermatitis, 226–228
Amevive Wisdom Acquired from Real-
World Evidence (AWARE) study
of alefacept for CPP, S107-S110
of alefacept safety, S139-S146
AWARE-2 extension of, S148-S152
of combination therapy with alefacept, S131-S137
efficacy outcomes of, S122-S130
methodology/characteristics of, S113-S121
Amputation, S12-S15
Analgesics, S40
Androgenetic alopecia, 262–264
Ankle-brachial index, S13
Antibiotics
for leg ulcer patients, S39
prophylaxis, in dermatologic surgery, 119–120
Anticoagulant therapy, 51–52
Antinuclear antibodies (ANAs), 82–86
Antiphospholipid antibody, S23
Antisense ribonucleic acid, 129–133
Antiseptic(s)
for leg ulcer patients, S40
techniques for surgery, 134–139
Antithrombin, S23
Arteriolopathy, calcific uremic, S29-S33
Atherosclerosis, lower extremity, S12-S15
ATP2C1 gene mutation, 151–153
Autoantibodies, non-organ-specific, 82–86
Autologous growth factors, 209–214
AWARE-2 registry, S148-S152
Azelaic acid, for PIH, 187
Basal cell carcinomas, 176–177
Baseline characteristics, for AWARE study, S113-S121
Biologic therapeutics
AWARE study on, S107-S110, S113-S121, S122-S130
AWARE-2 study on, S148-S152
combination therapy with, S131-S137
cost of, 303–307
for difficult-to-treat psoriasis, 6–15
for nail psoriasis, 1–4
for psoriasis, 283–292
safety of, S139-S146
Body surface area (BSA), 235–244, 283–292, 294–301
Botulinum toxin injections, 253–255
Brain metastases, 67–69
Breslow thickness, 57–58
Bullous pemphigoid, 280–282
Burden of illness, 235–244, 283–292, 294–301
Buried chip skin grafting, 164–168
Calcific uremic arteriolopathy (calciphylaxis), S29-S33
Calcineurin inhibitors, 140–145
Carcinoma(s)
lymphoepithelioma-like, 215–219
pigmented squamous cell, 326–328
skin, 22–31
symmetric basal cell, 176–177
See also Melanoma(s); Sarcoma(s)
Cardiovascular risk, with PAD, S14
Celiac disease, 53–54
Cellulitis, 43–47
C'ensil, 74–80
Central nervous system (CNS) metastases, 67–71
Chemical peels, for PIH, 188–189
Chest wall tuberculosis, 33–38
Children
granulomatous rosacea in, 115–118
hypopigmented mycosis fungoides in, 230–233
kaposiform hemangioendothelioma in, 155–158
soft tissue sarcoma in, 276–278
tanning behavior of, 22–31
Chinese medicaments, S40
Chronic actinic dermatitis (CAD), 121–128
Chronic microinjury, 176–177
Chronic osteomyelitis, S35-S37
Chronic plaque psoriasis (CPP)
alefacept for, S107-S110
AWARE study of, S113-S121
AWARE-2 registry and, S148-S152
combination therapy with alefacept, S131-S137
efficacy of alefacept for, S122-S130
safety of alefacept for, S139-S146
Chronic urticaria, 198–202
Chronic wounds, S26-S28
Classic Kaposi sarcoma, 18–21
Clinical Experience Acquired with Raptiva (CLEAR), 6–15
Clinical experience, with alefacept
AWARE study on, S107-S110
AWARE-2 registry and, S148-S152
baseline characteristics of, S113-S121
with combination therapy, S131-S137
efficacy outcomes, S122-S130
safety of, S139-S146
Closure, vacuum-assisted, 209–214
Coagulopathy, 155–158
Collagen
hypertrophic scar fibroblasts and, 129–133
nephrogenic fibrosing dermopathy and, 110–114
Common acquired symmetric hypermelanosis (melasma), 74–80
Community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA), 257–260
Comorbidities, with psoriasis, 235–244, 283–292
Condyloma acuminata, 151–153
Connective tissue disease, 82–86
Consumptive coagulopathy, 155–158
Contact allergy, and oral lichenoid lesions, 88–94
Contact dermatitis
aluminum, 226–228
chronic actinic dermatitis and, 121–128
in leg ulcer patients, S38-S41
Contiguous neuropathic ulcer, S35-S37
Corticosteroids
for Kasabach-Merritt syndrome (KMS), 155–158
leg ulcer patients and, S40
for pyoderma gangrenosum, S4-S9
tacrolimus ointment and, 140–145
Cost, of psoriasis treatment, 303–307
Critical limb ischemia, S12-S15
Crohn disease
acne inversa and, 164–168
pustular psoriasis and, 40–41
Cryoglobulinemia, mixed, S23
Cryosurgery, 269–271
Cutaneous leiomyomas, 102–105
Cutaneous protothecosis, 273–275
Cyclosporine, S4-S9
Depigmentation
of the scalp, 262–264
vitiligo and, 172–175
Dermal skin template, 102–105
Dermatology and melanoma, 56–57
Dermatology Life Quality Index (DLQI), 294–301
Dermopathy, nephrogenic fibrosing, 110–114
Dermoscopy, 326–328
Difficult-to-treat psoriasis, 6–15
Digital gangrene, 178–179
Dyes, S40
Efalizumab
for difficult-to-treat psoriasis, 11–15
for nail psoriasis, 3
for psoriasis, 106–108
Efficacy outcomes
in AWARE study, S122-S130
long-term, in AWARE-2 study, S148-S152
Elliptical excision, 56
Epidermodysplasia verruciformis (EV), 317–320
Epinephrine, 178–179
Erosive pustular dermatosis, 160–162
Erythematotelangiectatic rosacea, 266–271
Etanercept
for difficult-to-treat psoriasis, 8–9, 13–15
hidradenitis suppurativa and, 221–224
for nail psoriasis, 3
Ethyl chloride medium-stream spray, 253–255
Excision, elliptical, 56
Facial Afro-Caribbean childhood eruption (FACE), 115–118
Factor V Leiden, S21-S22
Factor XIII, S23-S24
Familial benign chronic pemphigus (Hailey-Hailey disease), 151–153
Fibrosis, skin, 110–114
Financial burden of psoriasis, 283–292, 294–301
Fitzpatrick skin types, and PIH, 183–190
Fragrances, S39
Gangrene, 178–179
Generalized eruptive histiocytoma (GEH), 146–149
Glycolic acid, 188–189
Gnatophyma, 266–271
Granulomatous periorificial dermatitis, 115–118
Granulomatous rosacea, 115–118
Hailey-Hailey disease, 151–153
Hemangioma
infantile, 276–278
lobular capillary, 181–182
Hematologic disorders, S20-S24
Hemodialysis, 110–114
Hepatitis C, S5-S6
Hereditary spherocytosis, S23
Hidradenitis suppurativa, 221–224
Histiocytosis
Langerhans cell, S17-S19, 43–47
non-Langerhans cell, 146–149
Homocysteine, S23
Hybrid tumors, 215–219
Hydradenitis suppurativa, 164–168
Hydroquinone, 186
Hyperhidrosis, 253–255
Hypermelanosis, 74–80
Hyperpigmentation, postinflammatory (PIH), 183–190
Hypertrophic scar fibroblasts, 129–133
Hypopigmented mycosis fungoides, 230–233
Immunosuppressive therapy
alefacept and, S139-S146
for bullous pemphigoid, 280–282
for Pneumocystis jiroveci pneumonia, 308–311
Infantile hemangioma, 276–278
Inflammatory bowel disease (IBD), S5-S6
Inflammatory plaques, 273–275
Infliximab
cost, for psoriasis, 303–307
for difficult-to-treat psoriasis, 9–10, 13–15
for hidradenitis suppurativa, 221–224
for nail psoriasis, 1–4
plantar pustular psoriasis and, 40–41
for pyoderma gangrenosum, S4-S9
Inguinal ulcers, S17-S19
Injection pain, 253–255
Interferon-α adjuvant therapy, 66–67
Interferon-γ release assay, 280–282
Intraoperative gamma probe (IOGP), 61, 62
Ischemic ulcers, S12-S15
Isotretinoin
for generalized eruptive histiocytoma, 146–149
for rosacea, 269–271
Juvenile hypopigmented mycosis fungoides, 230–233
Juveniles. See Children
Kaposi sarcoma, 18–21
Kaposiform hemangioendothelioma, 155–158
Kasabach-Merritt syndrome (KMS), 155–158
Langerhans cell histiocytosis (LCH) in adults, S17-S19
cellulitis-like, 43–47
L-ascorbic acid, 74–80
Laser treatment
for phymas, 269–271
for PIH, 188–189
Latent tuberculosis infection, 280–282
Leg, erosive pustular dermatosis, 160–162
Leg ulcers
contact dermatitis and, S38-S41
venous, S20-S24
Leiomyomas, cutaneous, 102–105
Lesions, oral lichenoid, 88–94
Leukoderma, scalp, 262–264
Lobular capillary hemangioma, 181–182
Locus minoris resistentiae, 313–315
Lower extremity atherosclerosis, S12-S15
Lupus anticoagulant, S24
Lupus vulgaris, 313–315
Lymph node basin, 321–325
Lymphangitis, 44–47
Lymphoepithelioma-like carcinomas, 215–219
Lymphoscintigraphy, 62–64
Malignancy, with EV and MDS, 317–320
Malignant tumors, 276–278
See also Sarcoma(s)
Melanocyte loss, 172–175
Melanocytic lesions, 326–328
Melanoma(s)
coexisting with tattoo pigment, 321–325
dermatology and, 56–57
dermatopathology for, 57–61
neuro-oncology for, 67–71
nuclear medicine and, 61–63
oncology for, 66–67
overview, 55–56
surgery for, 63–66
synchronous, 96–100
See also Carcinoma(s); Sarcoma(s)
Melasma, 74–80
Melasma Area and Severity Index (MASI), 75–80
Mental burden, of psoriasis, 283–292, 294–301
Metastases
central nervous system (CNS), 67–71
melanoma and, 321–325
Methicillin-resistant Staphylococcus aureus, 257–260
Microinjury, chronic, 176–177
Mixed cryoglobulinemia, S23
Mulltiple trichoepitheliomas, 169–171
Multidisciplinary wound care, S26-S28
Multiple cutaneous leiomyomas, 102–105
Mycobacterium tuberculosis, 280–282, 313–315
Mycosis fungoides, juvenile hypopigmented, 230–233
Myelodysplastic syndrome (MDS), 317–320
Nail psoriasis, 1–4
Nail Psoriasis Severity Index (NAPSI), 1–4
Nd:YAG laser, 181–182
Nephrogenic fibrosing dermopathy, 110–114
Neuro-oncology, 67–71
Nevus spilus, 96–100
Non-HIV/AIDs immunosuppressed patients, 308–311
Non-organ-specific autoantibodies, 82–86
Nuclear medicine, 61–63
Ocular rosacea, 266–271
Oncology, 66–67
Online surveys, 283–292, 294–301
Oral lichen planus, 88–94
Osteomyelitis, S35-S37
Otophyma, 266–271
Outcomes, in AWARE study, S122-S130
OVID Medline, 1–4
Pain
botulinum toxin injection, 253–255
control, S15
Palmar hyperhidrosis, 253–255
Papulopustular rosacea, 266–271
Patch-testing
for chronic actinic dermatitis, 121–128
for oral lichen planus, 88–94
Pemphigus vulgaris (PV), 82–86
Perineal ulcers, S17-S19
Perioperative antiseptic techniques, 134–139
Peripheral arterial disease (PAD), S12-S15
Phototherapy
alefacept and, S131-S137
cost, for psoriasis, 303–307
Phymatous rosacea, 266–271
Physical burden of psoriasis, 283–292, 294–301
Pigment, tattoo, 321–325
Pigmentary disorders, 183–190, 262–264
Pigmented squamous cell carcinoma, 326–328
Pimecrolimus, 160–162
Plantar hyperhidrosis, 253–255
Plantar pustular psoriasis, 40–41
Plaques, inflammatory, 273–275
Plewig and Kligman classification of rosacea, 266–271
Pneumocystis jiroveci pneumonia (PJP), 308–311
Postinflammatory hyperpigmentation (PIH), 183–190
Potency, of topical corticosteroids, 140–145
Preservatives, S39
Productivity, and psoriasis, 192–196
Prophylaxis
antibiotics for, 119–120
for Pneumocystis jiroveci pneumonia, 308–311
Protein C, S22
Protein S, S22-S23
Prototheca species, 273–275
Psoriasis
AWARE study and. See Amevive
Wisdom Acquired from Real-World
Evidence (AWARE) study
AWARE-2 study and, S148-S152
biologic therapeutics for, 6–15, 283–292
See also Biologic therapeutics
burden of illness with, 235–244, 283–292
efalizumab therapy for, 106–108
infliximab treatment for, 40–41
moderate-to-severe, 294–301
of the nail, 1–4
SKIN survey, 235–244
treatment cost comparison, 303–307
vitiligo and, 172–175
work productivity and, 192–196
Psoriasis Education Program (PEP), 283–292
p
survey, 235–244, 246–252
Psoriatic arthritis (PsA), 235–244
Pyoderma gangrenosum, S2-S9
Pyogenic granuloma, 181–182
Quality of life (QOL)
acne treatment adherence and, 204–208
psoriasis and, 235–244, 283–292, 294–301
Radiation therapy
adjuvant, for melanoma, 65–69
for classic Kaposi sarcoma, 18–21
Real-world use, of alefacept
AWARE study on, S107-S110
AWARE-2 study on, S148-S152
baseline characteristics of, S113-S121
with combination therapy, S131-S137
efficacy of, S122-S130
safety of, S139-S146
Renal failure, 110–114
Renal transplant patients, 209–214
Revascularization, S14
Rhabdomyosarcoma, 276–278
Rheumatoid arthritis, S5-S6
Rheumatologic symptoms, 235–244
Rhinophyma, 266–271
Rosacea, 266–271
Rosai-Dorfman disease, 146–149
Rubber, S39
Safety, of alefacept, S139-S146
Salicyclic acid, for PIH, 189
Sarcoidosis, 115–118
Sarcoma(s)
classic Kaposi, 18–21
soft tissue, 276–278
See also Carcinoma(s); Melanoma(s)
Scalp, leukoderma, 262–264
Scarring treatment, 129–133
Scleroderma ulcers, S42-S47
Senescent actinic depigmentation of the scalp, 262–264
Sentinel lymph node
biopsy, 59–66
tattoo pigment and metastatic melanoma in, 321–325
Serious adverse events (SAEs), with alefacept, S139-S146
SF-8 Health Survey, 294–301
Sickle cell disease, S23
Site of reduced resistance, 313–315
Skin and soft tissue abscesses (SSTAs), 257–260
Skin cancer, 22–31
Skin fibrosis, 110–114
Skin grafts, 164–168
SKIN survey telephone questionnaire, 246–252
Social burden of psoriasis, 283–292, 294–301
Sodium thiosulfate, S29-S33
Soft tissue sarcomas, 276–278
Spherocytosis, hereditary, S23
Spiradenocarcinomas, 215–219
Spiradenocylindromas, 215–219
Squamous cell carcinoma, 326–328
Staphylococcus aureus, 257–260
Steroids, systemic, 160–162
Surgery
antibiotic prophylaxis in, 119–120
anticoagulant therapy and, 51–52
for chest wall tuberculosis, 33–38
perioperative antiseptic techniques for, 134–139
for phymas, 269–271
Surgical resection
for malignant melanoma, 63–66
for multiple cutaneous leiomyomas, 102–105
Surveys, 235–244, 283–292, 294–301
Synchronous melanoma(s), 96–100
Syringomas, acral, 169–171
Systemic sclerosis, S42-S47
Systemic therapies, and alefacept, S131-S137
Tacrolimus ointment, 140–145
Tanning behavior, 22–31
Tape-stripping injury, 273–275
Tattoo pigment, 321–325
Tazarotene, 187
Teenagers, 22–31
Telephone SKIN survey questionnaire, 246–252
Thalassemia, S23
Therapy
anticoagulant, 51–52
biologic. See Biologic therapeutics
immunosuppressive, 280–282, 308–311
phototherapy, S131-S137, 303–307
radiation, 18–21, 65–69
topical, S39, S40, S131-S137, 204–208
See also Topical corticosteroids
Thrombocytopenia, 155–158
Thrombophilias, S20-S24
Toe-brachial index, S13
Topical acne therapy, 204–208
Topical antibiotics, S39
Topical Chinese medicaments, S40
Topical corticosteroids
for erosive pustular dermatosis, 160–162
tacrolimus ointment and, 140–145
Transepidermal water loss (TEWL), 75–80
Tretinoin, for PIH, 186
Trichoepitheliomas, 169–171
Trimethoprim-sulfamethoxazole (TMP-SMX), 308–311
Tuberculosis
cutaneous, lupus vulgaris and, 313–315
latent, screening for, 280–282
surgical management of, 33–38
Tumor necrosis factor α (TNF-α), 48–49
Tyrosinase inhibitors, 186–187
Ulcers
chronic perineal and inguinal, S17-S19
contiguous neuropathic, S35-S37
leg, contact dermatitis in, S38-S41
lower extremity, S12-S15
scleroderma, S42-S47
venous leg, S20-S24
Ultraviolet-induced scalp leukoderma, 262–264
Urticaria, chronic, 198–202
Vacuum-assisted closure, 209–214
Venous leg ulcers, S20-S24
Vibrio vulnificus, 209–214
Vincristine, 155–158
Vitiligo
juvenile hypopigmented mycosis fungoides and, 230–233
psoriasis and, 172–175
Wegener granulomatosis, 308–311
Work productivity, 192–196, 283–292
Wound care
chronic, multidisciplinary approach, S26-S28
for ischemic ulcers, S15
Youth. See Children
Author Index
Alanen, Kenneth, 55
Alfaioli, Barbara, 326
Al-Khenaizan, Sultan, 276
Al-Mubarak, Luluah, 276
Altintas, Suleyman, 169
Andrew, Robin, 294
Atik, Esin, 169
Azari, Rahman, 134
Babcock, Kelly, 303
Balagurusamy, Madhan, 204
Balci, Didem Didar, 169
Beach, Renée A., 121
Beatch, Anita, 313
Bédard, Marie, Sophie, 181
Bhardwaj, Minakshi, 43
Bin, Shu, 129
Bishburg, Eliahu, 257
Bissonnette, Robert, S107, S113, S122, S131, S139, S148
Bleiziffer, Oliver, 164
Blondin, David A., 82
Boulanger, Jean, 181
Brassard, Alain, S2, S17, S20, S29, S42, 308
Brodbaker, Elliott, 226
Browne, L. Walden, 321
Brown-Maher, Tracey, S26
Bruce, Alison J., 53
Çaylak, Hasan, 33
Chan, Brian, 192
Chan, Daphne, 294
Chan, Trini, 257
Chao-quan, Luo, 129
Cheney, Richard T., 96
Chetty, Runjan, 215
Cheung-Lee, Melody, 313
Chiu, Melvin W., 266
Chu, Paul, 151
Claveau, Joël, 55
Cohen, Steven R., 151
Courtney, Mark, S29
Dakak, Mehmet, 33
Danopoulou, Ifigenia, 198
de Giorgi, Vincenzo, 326
DeKoven, Joel, 146
Demirkesen, Cuyan, 160
DesGroseilliers, Jean-Pierre, 303
Al-Doukhi, Azari, 172
Dragu, Adrian, 164
Drucker, Aaron M., 155
Eisen, Daniel B., 134
English, Penny Lovell, 40
Ezra, Navid, 266
Ferreira, Gustavo N., 317
Festa, Cyro, 317
Fraquelli, Elisa, 294
Fratesi, Lauren, 119
Fritzler, Marvin J., 82
Fung, Karen, 204
Genç, Onur, 33
George, Ralph, 55
Gerstein, William, 18
Ghazarian, Danny, 215
Gilbert, Ralph, 215
Gilliam, Anita C., 115
Gkouvi, Aikaterini, 198
Goodfellow, Alfred, 280
Gordeon, Danielle, 22
Gözübüyük, Alper, 33
Gravvanis, Andreas, 102
Grazzini, Marta, 326
Greco, Joseph F., 266
Gregoriou, Stamatis, 198
Grewal, Parbeer, 308
Grimes, Pearl, 183
Grushka, Miriam, 88
Guenther, Lyn, 22, 235
Gulliver, Wayne, S113, S139, 204
Gupta, Aditya K., 204
Gurbuz, Oya, 160
Gürkök, Sedat, 33
Habeeb, Ayman Al, 110
Haber, Richard M., 230
Hales, Brigette, 192
Haley, Jennifer C., 266
Hauerstock, David, 18
Hayes, Robert C., 280
Ho, Vincent, 192
Horch, Raymund E., 164
Hou, Haiyan, 82
Hou-dong, Li, 129
Hui-zhen, Liang, 129
Humphrey, Shannon, 273
Hwang, Seon-Wook, 74
Ijacu, Horia, 283
Im, Sungbin, 183
Jackson, Christine, 235, 283
Jaigirdar, Adnan A., 321
Janowska, Agata, 326
Jean, Sara Elisabeth, S38
Ju-lin, Xie, 129
Kakagia, Despoina, 102, 176, 209
Kalisiak, Michal, S29
Kalogeromitros, Dimitris, 198
Kane, John M., III, 96
Kanigsberg, Nordau, 48
Kar, Hemanta Kumar, 43
Karanikola, Evmorfia, 106
Katsambas, Andreas, 198
Katsarou, Alexandra, 198
Kavakli, Kuthan, 33
Keeling, Douglas N., 280
Kim, Jung-Wook, 74
Kirshen, Carly, 48
Kiss, Alex, 140
Kneser, Ulrich, 164
Kontochristopoulos, George, 198
Korman, Neil J., 115
Kriki, Pelagia, 209
Kwinter, Jennifer, 146
Landells, Ian, S107, S113, S122, S131, S139, S148
Langley, Richard G., S139
Lee, Deborah, 74
Lee, Mao-Cheng, 313
Leong, Stanley P.L., 321
Levitt, Jacob, 140
Lim, Joyce, 183
Lin, Andrew, S29
Lipoff, Jules B., 151
Lomaga, Mark A., 88
Long, Richard, 313
Lotti, Torello, 326
Lucas, Chere R., 115
Lui, Harvey, S113, S122, S131, 183, 273
Lynde, Carrie B., 53
Lynde, Charles, 6, S113, 192, 204, 235
Macdonald, Jillian, 178
Mahant, Sanjay, 155
Mahler, Ronald, 283
Mallouris, Andreas, 176
Man, Jeremy, S2
Martinka, Magdalena, 273
Mason, Warren P., 55
Massi, Daniela, 326
McMurtry, Sean M., S12
Meguerditchian, Ari-Nareg, 96
Mikhael, Dalia, 303
Mittmann, Nicole, 192
Moreau, Linda, S38
Mourvati, Euthymia, 209
Mudgil, Adarsh V., 151
Murray, Joseph A., 53
Al-Mutairi, Nawaf, 172
Mydlarski, P. Régine, 82
Nalmas, Sandhya, 257
Ngo, Jennifer T., 230
Noiles, Kristin, 1
Oh, Doo-Jin, 74
Oliveira, Walmar R., 317
Özpolat, Berkant, 33
Pagedar, Nitin A., 215
Papaconstantis, Markos, 106
Papadopoulos, Stefanos, 102
Papaioannou, Dimitrios, 198
Papi, Federica, 326
Papp, Kim, S113, S131, S139, 294
Pappas, Lisa, 140
Park, Sung-Wook, 74
Parsons, Laurie M., S35
Partington, Sara, 110
Passadakis, Ploumis, 209
Perez-Ordonez, Bayardo, 215
Poelman, Susan M., S17
Polak, Shely, 88
Pope, Elena, 155
Poulin, Yves, S139, 192, 204, 221, 235, 294
Prajapati, Vimal, S2
Pratt, Melanie D., 121, 226
Rady, Peter L., 317
Rallis, Efstathios, 106
Ramien, Michele, S42
Richards, Robert N., 253
Rigopoulos, Dimitrios, 198
Rogers, Roy S., III, 53
Rosenthal, Donald, 110
Sabhnani, Sunil, 43
Salama, Samih, 110
Sapra, Sheetal, 204
Searles, Gordon, S107, S113, S122, S131, S139, S148
Sebaldt, Rolf J., 204
Seckin, Dilek, 160
Shah, Monica, 257
Shao-hai, Qi, 129
Sharifi, Emile, 321
Sharma, Prafulla Kumar, 43
Shear, Neil H., S107, S113, S122, S131, S139, S148, 192
Shideler, Karalee K., 82
Smylie, Michael, 55
Stavrianeas, Nikolaos, 198
Taher, Zaki A., S20
Taillefer, Raymond, 55
Tan, Jerry K.L., 204
Taylor, Susan, 183
Theodoridis, Marios, 209
Thodis, Elias, 209
Thomas, D. Richard, 204
Tian-zeng, Li, 129
Trotter, Martin J., 230
Tsoutsos, Dimosthenis, 102
Tyring, Stephen K., 317
Valaskatzi, Argyro, 106
Vargemezis, Vassilios, 209
Vender, Ronald, 1, 40, S122
Verma, Shyam B., 262
Verros, Constantinos, 106
Vuong, Te, 18
Waldron, John, 215
Walsh, Scott, 88
Warshawski, Laurence, 134
Wasel, Norman, 294, 313
Weatherhead, Louis, 51, 119, 178
Webster, Duncan, 280
Weinstein, Miriam, 155
Wexler, Denise, S139
Wollina, Uwe, 262
Wong, Ralph, 55
Xu-sheng, Liu, 129
Yeh, Michael W., 321
Yiacoumettis, Andreas, 176
Ying-bin, Xu, 129
Yong, Huang, 129
Young, Saryna, 151
Yücel, Orhan, 33
Zhang, Zuhui, 82
Zloty, David, 134